Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Polymer coatings shield drugs from the stomach's acidic environment by preventing premature drug release in the gastric milieu. This protection allows unstable drugs to pass safely through the stomach to regions where they can be more effectively absorbed, thereby improving bioavailability and therapeutic effectiveness.

Beta-cyclodextrins enhance drug stability by forming inclusion complexes with poorly soluble drugs. These complexing agents significantly increase drug solubility and stability, improving bioavailability by making drugs more available for absorption in the gastrointestinal tract. This approach represents a key bioavailability enhancement strategy.

Bioadhesive delivery systems adhere to mucosal surfaces, prolonging the drug's presence in the gastrointestinal tract. By increasing contact time with epithelial surfaces, these systems allow for sustained drug release and improved absorption. This enhanced retention significantly improves overall bioavailability and therapeutic outcomes.

Co-administering metabolism inhibitors prevents premature drug degradation in the gastrointestinal tract and liver. For example, erythromycin significantly enhances cyclosporin bioavailability by inhibiting its metabolism, allowing more drug to reach systemic circulation. This strategy improves therapeutic effectiveness by reducing drug loss.

Gastro-retentive drug delivery systems localize the delivery device in the stomach or small intestine, extending the drug's residence time at absorption sites. This prolonged localization ensures the drug remains in optimal regions longer, significantly improving bioavailability. These systems enhance therapeutic effectiveness by maximizing absorption opportunities.

Swelling excipients such as cellulose ethers and natural gums expand upon contact with gastric fluids, increasing their size and retention within the stomach. This swelling prolongs stomach residence time, delays intestinal transit, and increases epithelial contact, allowing improved drug absorption and effectiveness.

Controlled-release microencapsulated systems provide sustained drug release by encapsulating the drug and releasing it gradually over time. Unlike standard delivery, these systems maintain therapeutic drug levels longer in the gastrointestinal tract, improving bioavailability and reducing dosing frequency requirements while enhancing patient compliance.